Daniela Cilloni
YOU?
Author Swipe
View article: Ibrutinib-Associated Liver Injury in a Patient with Chronic Lymphocytic Leukemia: Clinical Course and Therapeutic Approach
Ibrutinib-Associated Liver Injury in a Patient with Chronic Lymphocytic Leukemia: Clinical Course and Therapeutic Approach Open
Background: Ibrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi), has revolutionized the treatment of Chronic Lymphocytic Leukemia (CLL), yet hepatotoxicity remains a rare and poorly characterized adverse event. Case Presentation: We rep…
View article: UBE2O AS A KEY REGULATOR OF DRUG-INDUCED ERYTHROPOIESIS IN THE CONTEXT OF MYELODYSPLASTIC SYNDROMES
UBE2O AS A KEY REGULATOR OF DRUG-INDUCED ERYTHROPOIESIS IN THE CONTEXT OF MYELODYSPLASTIC SYNDROMES Open
Ineffective erythropoiesis and the resulting anemia are the main characteristics of myelodysplastic syndromes (MDS). Drugs designed to promote erythropoiesis in MDS patients include erythropoiesis-stimulating agents such as recombinant hum…
View article: The Dual Role of Interferon Signaling in Myeloproliferative Neoplasms: Pathogenesis and Targeted Therapeutics
The Dual Role of Interferon Signaling in Myeloproliferative Neoplasms: Pathogenesis and Targeted Therapeutics Open
Interferons (IFNs) are pleiotropic cytokines involved in antiviral defense, immune regulation, and tumor suppression. In myeloproliferative neoplasms (MPNs) and related disorders—including classical BCR, ABL1-negative MPNs, chronic myeloid…
View article: Real World Study on the Best <scp>CPX</scp> ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation
Real World Study on the Best <span>CPX</span> ‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation Open
In the registration clinical trial 301 (NCT01696084), CPX‐351 has shown to be superior to conventional 3 + 7 in secondary AML (s‐AML). However, the optimal duration of treatment, the best timing for allogeneic stem cell transplantation (al…
View article: Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the <scp>GIMEMA LabNet CML</scp> Network Database
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the <span>GIMEMA LabNet CML</span> Network Database Open
NA
View article: Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers Open
Background/Objectives: The aim of this study was to assess the unmet needs of myelodysplastic neoplasm (MDS) patients and their caregivers, focusing on how these needs impact quality of life (QoL) and daily functioning. MDS predominantly a…
View article: Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers Open
Background/Objectives: This study aimed to assess the unmet needs of myelodysplas-tic neoplasm (MDS) patients and their caregivers, focusing on how these needs impact quality of life (QoL) and daily functioning. MDS predominantly affects o…
View article: Upfront intensive treatment analysis of the Italian Cohort Study on <i>FLT3</i>‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting
Upfront intensive treatment analysis of the Italian Cohort Study on <i>FLT3</i>‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting Open
Background The addition of a FLT3 inhibitor (FLT3i) to standard chemotherapy to treat fit newly diagnosed (ND) patients with FLT3 ‐mutated acute myeloid leukemia (AML) represents the standard of care resulting from clinical trial results. …
View article: Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
Impact of Pre‐Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents Open
Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.
View article: Tyrosine Kinase Inhibitor Therapy Enhances Stem Cells Profile and May Contribute to Survival of Chronic Myeloid Leukemiastem Cells
Tyrosine Kinase Inhibitor Therapy Enhances Stem Cells Profile and May Contribute to Survival of Chronic Myeloid Leukemiastem Cells Open
Background/Objectives: Treatment with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has revolutionized disease management and has transformed CML from a life-threatening disease to a chronic condition for many patient…
View article: Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report
Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report Open
Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm characterized by CSF3R mutations. Here, we report the first case of a CNL patient positive for a de-novo germline CSF3R T618I variant effectively treated with ruxoli…
View article: Detection of KIT Mutations in Systemic Mastocytosis: How, When, and Why
Detection of KIT Mutations in Systemic Mastocytosis: How, When, and Why Open
More than 90% of patients affected by mastocytosis are characterized by a somatic point mutation of KIT, which induces ligand-independent activation of the receptor and downstream signal triggering, ultimately leading to mast cell accumula…
View article: The Ubiquitin-Conjugating Enzyme E2 O (UBE2O) and Its Therapeutic Potential in Human Leukemias and Solid Tumors
The Ubiquitin-Conjugating Enzyme E2 O (UBE2O) and Its Therapeutic Potential in Human Leukemias and Solid Tumors Open
Protein degradation is a biological phenomenon essential for cellular homeostasis and survival. Selective protein degradation is performed by the ubiquitination system which selectively targets proteins that need to be eliminated and leads…
View article: Detection of C-KIT Mutations in Systemic Mastocytosis: How, When and Why
Detection of C-KIT Mutations in Systemic Mastocytosis: How, When and Why Open
More than 90% of patients affected by mastocytosis are characterized by a somatic point mutation of c-KIT, which induces ligand-independent activation of the receptor and downstream signal triggering, ultimately leading to mast cell prolif…
View article: Cerebral Vein Thrombosis and Direct Oral Anticoagulants: A Review
Cerebral Vein Thrombosis and Direct Oral Anticoagulants: A Review Open
Cerebral venous thrombosis (CVT) is a rare type of cerebrovascular event in which the thrombosis occurs in a vein of the cerebral venous system. The diagnosis could be challenging due to the great clinical variability, but the outcome is f…
View article: The Controversial Role of Ubiquitin-Conjugatin Enzyme E2 O (UBE2O) in Human Leukemias and Solid Tumors
The Controversial Role of Ubiquitin-Conjugatin Enzyme E2 O (UBE2O) in Human Leukemias and Solid Tumors Open
Protein degradation is a biological phenomena essential for cellular homeostasis and survivor. Selective protein degradation is performed by the ubiquitination system which selectively target proteins that need to be eliminated and lead th…
View article: A Radiation-Free Approach Based on the Whole-Body MRI Has Shown a High Level of Accuracy in the Follow-Up of Lymphoma Patients—A Single Center Retrospective Study
A Radiation-Free Approach Based on the Whole-Body MRI Has Shown a High Level of Accuracy in the Follow-Up of Lymphoma Patients—A Single Center Retrospective Study Open
Background: Recurrence, even after years from the last treatment, characterizes lymphoproliferative disorders. Therefore, patients in complete remission from the disease should be followed up with periodic clinical checks. There is not a c…
View article: First-hit <i>SETBP1</i> mutations cause a myeloproliferative disorder with bone marrow fibrosis
First-hit <i>SETBP1</i> mutations cause a myeloproliferative disorder with bone marrow fibrosis Open
SETBP1 mutations are found in various clonal myeloid disorders. However, it is unclear whether they can initiate leukemia, because SETBP1 mutations typically appear as later events during oncogenesis. To answer this question, we generated …
View article: Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach
Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach Open
Acute myeloid leukemia (AML) is a complex hematologic malignancy with high morbidity and mortality. Nucleophosmin 1 (NPM1) mutations occur in approximately 30% of AML cases, and NPM1-mutated AML is classified as a distinct entity. NPM1-mut…
View article: Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy Open
Background Anemia is frequently present in patients with myelofibrosis (MF), and it may be exacerbated by treatment with the JAK2 ‐inhibitor ruxolitinib (RUX). Recently, a relevant blast phase (BP) incidence has been reported in anemic MF …
View article: First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Open
Somatic SETBP1 mutations are found in various myeloid disorders covering both myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS). To characterize the early steps of SETBP1-mediated leukemogenesis, we generated a conditi…
View article: Safety and Efficacy of New Drugs Combinations in Newly Diagnosed Multiple Myeloma with Renal Failure at Onset: A Retrospective Multicentric Study
Safety and Efficacy of New Drugs Combinations in Newly Diagnosed Multiple Myeloma with Renal Failure at Onset: A Retrospective Multicentric Study Open
Renal injury at onset of newly diagnosed multiple myeloma (NDMM) is associated with poor outcome. Patients with severe renal failure due to MM are excluded from clinical trials with new drugs. The aim of this retrospective study was to des…
View article: A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis Open
Most patients with myelofibrosis (MF) discontinue ruxolitinib (JAK1/JAK2 inhibitor) in the first 5 years of therapy due to therapy failure. As the therapeutic possibilities of MF are expanding, it is critical to identify patients predispos…
View article: A Leukemic Target with a Thousand Faces: The Mitochondria
A Leukemic Target with a Thousand Faces: The Mitochondria Open
In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones wit…
View article: Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey Open
Unmet needs remain in later lines chronic myeloid leukemia (CML): the response rate and the overall survival of resistant patients in the chronic phase who changed a second-generation TKI in the second line with another TKI with similar ac…
View article: PB2672: EXPLORING UNMET NEEDS OF PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY
PB2672: EXPLORING UNMET NEEDS OF PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY Open
Topic: 35. Quality of life and palliative care Background: One of the main goals of treatment for patients with myelodysplastic neoplasms (MDS) is maintaining/improving quality of life (QoL). It is known that transfusion dependence impacts…
View article: PB2177: MULTICENTRE RETROSPECTIVE OBSERVATIONAL STUDY ON PATIENTS WITH MYELOFIBROSIS IN PIEDMONT. ROLE OF INFLAMMATION AND DYSIMMUNITY. MFACTORS STUDY.
PB2177: MULTICENTRE RETROSPECTIVE OBSERVATIONAL STUDY ON PATIENTS WITH MYELOFIBROSIS IN PIEDMONT. ROLE OF INFLAMMATION AND DYSIMMUNITY. MFACTORS STUDY. Open
Topic: 15. Myeloproliferative neoplasms - Biology & Translational Research Background: Primary Myelofibrosis is a clonal myeloproliferative neoplasm (MPNs) characterized by megakaryocytic and granulocytic hyperplasia that goes along with p…
View article: P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING
P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING Open
Background: Midostaurin in combination with standard chemotherapy represents the standard of care for the treatment of newly-diagnosed (ND) FLT3-mutated Acute Myeloid Leukemia (AML) patients. However, data on the effectiveness of upfront F…
View article: Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts Open
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts
View article: Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome Open
Background Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype. Aims and Methods Prognostic correlates of cytopenic phenotype we…